Hereditary Angioedema News

Hereditary Angioedema - Market Insights, Epidemiology and Market ... - PR Newswire (press release)



Hereditary Angioedema - Market Insights, Epidemiology and Market ... 
PR Newswire (press release)
LONDON, Oct. 23, 2017 /PRNewswire/ -- DelveInsight's "Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast ? 2025" report provides ...

and more » 


Shire to Present New Data to Help Advance Understanding of Rare Diseases - GlobeNewswire (press release)



Shire to Present New Data to Help Advance Understanding of Rare Diseases 
GlobeNewswire (press release)
Cambridge, MA - Oct 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, announced today new data from the company's hereditary angioedema (HAE) and primary immunodeficiency (PI) portfolios and pipeline will ...

and more » 


Leading pharmaceutical executive Dr. Robert Karr joins Verseon's Board of Directors - Markets Insider



Leading pharmaceutical executive Dr. Robert Karr joins Verseon's Board of Directors 
Markets Insider
Dr. Karr had been a member of Verseon's Scientific Advisory Board, and has helped shape Verseon's four drug programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. Dr. Karr's considerable experience across the drug ...

and more » 


Global Hereditary Angioedema Market 2017 Industry Key Players, Share, Trend, Segmentation, Analysis & Forecast to ... - Medgadget (blog)



Global Hereditary Angioedema Market 2017 Industry Key Players, Share, Trend, Segmentation, Analysis & Forecast to ... 
Medgadget (blog)
?Hereditary Angioedema ? Market Insights, Epidemiology and Market Forecast ? 2025? report provides an overview of the disease and in depth research related to Hereditary Angioedema for the 7MM (United States, Germany, France, Italy, Spain and UK) for ...

and more » 


Hereditary Angioedema (HAE)-Pipeline Insights, 2017 - Medgadget (blog)



Hereditary Angioedema (HAE)-Pipeline Insights, 2017 
Medgadget (blog)
Hereditary Angioedema (HAE)-Pipeline Insights, 2017?, report provides in depth insights on the pipeline drugs and their development activities around the Hereditary Angioedema (HAE). The DelveInsight'sReport covers the product profiles in various ...

 


Pharming Announces Warrant Exercises and Conversions of its Ordinary Bonds into Shares Mostly Through Cashless ... - MarketWatch



Pharming Announces Warrant Exercises and Conversions of its Ordinary Bonds into Shares Mostly Through Cashless ... 
MarketWatch
Pharming's lead product, RUCONEST(R) (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema ("HAE") attacks in patients in Europe, the US, Israel and South Korea. The product is available ...

and more » 


AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic ... - GlobeNewswire (press release)



AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic ... 
GlobeNewswire (press release)
LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AntriaBio, Inc. (?AntriaBio? or the ?Company?) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant unmet medical needs, today announced that it is ...

and more » 


Hereditary Angioedema Market Overview, Growth, Supply and Forecast 2021 - Medgadget (blog)



Hereditary Angioedema Market Overview, Growth, Supply and Forecast 2021 
Medgadget (blog)
This hereditary angioedema market provides analysis of size, share, trends, value, volume, country coverage, key leading players (Shire Plc, iBio,Inc., Pharming Group NV, CSL Limited) & Mars Incorporated) market dynamics, competitive landscape and ...

 


Global Hereditary Angioedema Drug Market 2017: CSL Limited, Inc., Ionis Pharmaceuticals, BioCryst Pharmaceuticals ... - News of Columnist: Research News By Market.Biz



News of Columnist: Research News By Market.Biz
 
Global Hereditary Angioedema Drug Market 2017: CSL Limited, Inc., Ionis Pharmaceuticals, BioCryst Pharmaceuticals ... 
News of Columnist: Research News By Market.Biz
Global Hereditary Angioedema Drug Market 2017 Research Report presents a professional and deep analysis on the present state of Hereditary Angioedema Drug Market 2017 in Pharmaceuticals and Healthcare Industry. High Use of Hereditary ...

 


The Vision Is Clear: Listen To Merck And Invest In Microcap KalVista Pharmaceuticals - Seeking Alpha



Seeking Alpha
 
The Vision Is Clear: Listen To Merck And Invest In Microcap KalVista Pharmaceuticals 
Seeking Alpha
KalVista is a small, thinly traded biotech company that is developing plasma kallikrein inhibitors to treat hereditary angioedema (NYSE:HAE) and diabetic macular edema (DME). I must admit, until the recent partnership with Merck (MRK) was announced ...
Rajeev M. Shah Purchases 850000 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock TrueBlueTribune
EPS for Points International Ltd. (PTS) Expected At $0.06; Kalvista Pharmaceuticals (KALV) SI Decreased By 5.45% UtahHerald.com

all 4 news articles »